title: Association between paraoxonase activity and late saphenous vein graft occlusion in patients with coronary artery bypass grafting.
abstract: BACKGROUND
  Coronary vein graft disease is an important contributor to the morbidity after coronary artery bypass grafting (CABG). Late occlusion of the graft is a serious complication that limits the use of the saphenous vein as a coronary bypass conduit. It is frequently encountered in old, degenerated vein grafts with advanced atherosclerotic plaque formation. Paraoxonase-1 (PON-1) is an HDL-bound enzyme which has anti-atherogenic properties and protects LDL cholesterol from oxidative modification.
  
  
  OBJECTIVE
  To examine the association between PON-1 activity and late saphenous vein graft occlusion.
  
  
  METHODS
  Thirty-eight patients who had at least one occluded saphenous vein graft (group 1; 12 females, 26 males) and 41 patients who had a patent saphenous vein graft (group 2; 7 females, 34 males) were enrolled in this study. Paraoxonase activity was measured spectrophotometrically.
  
  
  RESULTS
  The mean PON-1 activity in group 1 was significantly lower than in group 2 (74.1 +/- 52.1 vs. 114.4 +/- 90.9 U/l, p = 0.02). The mean platelet volume was significantly higher in group 1 than group 2 (8.8 +/- 1.6 vs. 8.2 +/- 1.1 fl, p = 0.04). Multiple logistic regression analysis showed that only PON-1 activity (beta = 0.011, p = 0.042) was an independent predictor of late occlusion of a saphenous vein graft.
  
  
  CONCLUSIONS
  Our results show that PON-1 activity is lower in patients with late saphenous vein graft occlusion. Reduced PON-1 activity may lead to acceleration of saphenous vein graft occlusion.
authors.affiliation: Department of Cardiology, Ministry of Health, Diskapi Yildirim Beyazit Research and Educational Hospital, Ankara, Turkey.
authors.forename: Goksel
authors.initials: G
authors.lastname: Cagirci
authors.forename: Serkan
authors.initials: S
authors.lastname: Cay
authors.forename: Ozlem
authors.initials: O
authors.lastname: Karakurt
authors.forename: Nuray
authors.initials: N
authors.lastname: Yazihan
authors.forename: Cengiz
authors.initials: C
authors.lastname: Aydin
authors.forename: Sadik
authors.initials: S
authors.lastname: Acikel
authors.forename: Mehmet
authors.initials: M
authors.lastname: Dogan
authors.forename: Harun
authors.initials: H
authors.lastname: Kilic
authors.forename: Serkan
authors.initials: S
authors.lastname: Topaloglu
authors.forename: Dursun
authors.initials: D
authors.lastname: Aras
authors.forename: Ramazan
authors.initials: R
authors.lastname: Akdemir
mesh_terms: D000368:Aged; D043303:Aryldialkylphosphatase / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003324:Coronary Artery Disease / Q000201:enzymology* / Q000601:surgery*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000201:enzymology* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland; D012501:Saphenous Vein; D013053:Spectrophotometry
chemical_list: D015415:Biomarkers; D043303:Aryldialkylphosphatase